«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年01期

页码:

39-43

栏目:

临床医学

出版日期:

2020-04-06

文章信息/Info

Title:

Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer

文章编号:

1006-8147(2020)01-0039-05

作者:

王银蕾¹; 2; 杨 瀚¹; 高 杰¹ ; 王玉杰¹; 2; 沈 冲¹; 2; 吴周亮¹; 2; 田大伟¹; 胡海龙¹; 2

（1.天津医科大学第二医院泌尿外科，天津 300211；2.天津医科大学第二医院中心实验室，天津 300211)

Author(s):

WANG Yin-lei¹; 2;  YANG Han¹;  GAO Jie¹;  WANG Yu-jie¹; 2;  SHEN Chong¹; 2;  WU Zhou-liang¹; 2;  TIAN Da-wei¹;  HU Hai-long¹; 2

（1. Department of Urology, The Second Hospital, Tianjin Medical University, Tianjin 300211, China; 2. Central Laboratory, The Second Hospital，Tianjin Medical University, Tianjin 300211, China)

关键词:

同源结构域转录因子2; 膀胱癌; DNA甲基化; 预测标记物; 预后

Keywords:

homology domain transcription factor 2;  bladder cancer;  DNA methylation;  predictive marker;  prognosis

分类号:

R737.14

DOI:

-

文献标志码:

A

摘要:

目的：由于近些年表观遗传学的发展，基因启动子甲基化检测在预测癌症诊断预后方面拥有巨大的潜力。PITX2启动子的高CpG岛增加其甲基化程度，其能够成为新的膀胱癌预测因子。方法： QRT-PCR检测永生化膀胱上皮细胞系（SV-HUC）和3种膀胱癌细胞系（EJ、5637、T24）以及癌组织和癌旁组织的差异性表达。通过DNA甲基化测定实验对33例全膀胱切除术切除癌组织进行甲基化程度测定，分为大于50%甲基化，小于50%甲基化建立甲基化程度与肿瘤分期分级的联系。结果：使用实时定量RT-PCR（Q-PCR）证明PITX2在膀胱癌细胞中高表达。癌组织中甲基化程度明显高于癌旁组织。PITX2启动子甲基化与肿瘤大小（P =0.026 7）、高级别（P =0.027 7）和TNM分期（0.016 0）显着相关。在预测肿瘤侵袭（T2-T4肿瘤）中，PITX2启动子甲基化的ROC曲线下面积（AUC）为0.867。 Kaplan-Meier生存分析表明，与低PITX2甲基化表达的肿瘤相比，高PITX2启动子甲基化表达的肿瘤与较短的总体存活相关。结论：PITX2在膀胱癌组织中异常高表达，并且PITX2启动子区域在癌组织中存在高甲基化是患者不良预后的独立危险因素，因此，PITX2启动子甲基化可能成为膀胱癌肿瘤发生进展有效的预测因子。

Abstract:

Objective: Due to the development of epigenetics in recent years, gene promoter methylation detection has great potential in predicting the prognosis of cancer. The high CpG island of the PITX2 promoter increases its rate of methylation, which can be a new predictor of bladder cancer. Methods: QRT-PCR was used to detect differential expression of immortalized bladder epithelial cell line (SV-HUC) and three bladder cancer cell lines (EJ, 5637, T24) as well as cancerous and paracancerous tissues. The methylation rates of 33 cases of total cystectomy was determined by DNA methylation assay, which was divided into more than 50% methylation, less than 50% methylation to establish the degree of methylation and tumor staging. Results: Real-time quantitative RT-PCR(Q-PCR) was used to demonstrate hypermethylation of the PITX2 promoter in bladder cancer cells. The degree of methylation in bladder cancer tissues is significantly higher than that in adjacent tissues. PITX2 promoter methylation was significantly associated with tumor size (P =0.026 7), high grade (P =0.027 7), and TNM stage (0.016 0). In the prediction of tumor invasion (T2-T4 tumor), the area under the ROC curve (AUC) of the PITX2 promoter methylation was 0.867. Kaplan-Meier survival analysis indicated that tumors with high PITX2 promoter methylation expression were associated with shorter overall survival compared to tumors with low PITX2 methylation expression. Conclusion: Our results suggest that hypermethylation of the PITX2 promoter region is highly expressed in bladder cancer tissues, and high expression is an independent risk factor for poor prognosis in patients. Therefore, PITX2 promoter methylation may be a treatment for high-grade bladder. An effective predictor of cancerous tumors.

参考文献/References:

[1] Rebecca L, Kimberly D, Ahmedin J, et al. Cancer statistics, 2018[J]. Cancer J Clinical, 2018，68: 7
[2] Logan M, Pagán-Westphal S M, Smith D M, et al. The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals[J]. Cell, 94 (3): 307
[3] Héon E, Sheth B P, Kalenak J W, et al. Linkage of autosomal dominant iris hypoplasia to the region of the Rieger syndrome locus (4q25) [J]. Human Molecular Genetics, 1995，4(8): 1435
[4] Kioussi C, Briata P, Baek S H, et al. Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development[J]. Cell, 2002, 111 (5): 673
[5] Baek S H, Kioussi C, Briata P, et al. Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway[J].Proc Natl Acad Sci USA, 2003,100(6):3245
[6] Sun Y M, Wang J, Qiu X B, et al. PITX2 loss of function mutation contributes to tetralogy of Fallot[J]. Gene, 2016,577(2):258
[7] Zhao C M, Peng L Y, Li L, et al. PITX2 Loss-of-Function mutation contributes to congenital endocardial cushion defect and Axenfold-Rieger syndrome[Z]. PLoS One，2015,10(4):e0124409
[8] Wei D, Gong X H, Qiu G, et al. Novel Pitx2c loss-of-function mutations associated with complex congenital heart disease[Z]. Int J Mol Med，2014，33(5):1201
[9] Esteller M. Cancer epigenomics: DNA methylomes and histone- modification maps[J]. Nat Rev Genet, 2007,8(4):286
[10] Baylin S B. DNA methylation and gene silencing in cancer[Z]. Nat Clin Pract Oncol, 2005（2 Suppl 1）:S4
[11] Esteller M. Epigenetics in cancer[J]. The New England Journal of Medical，2008，358:1148
[12] Widschwendter M, Jones P A. DNA methylation and breast carcinogenesis[J]. Oncogene, 2002,21(35):5462
[13] Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling[J]. Nature, 2002, 417(6889): 664
[14] Dietrich D, Hasinger O, Liebenberg V, et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients[J]. Diagn Mol Pathol, 2012,21(2):93
[15] Eva J, Karol K, Pavol Z, et al, Methylation in promoter regions of PITX2 and RASSF1A genes in association with clinicopathological features in breast cancer patients[J]. Tumor Biology, 2016, 37:15707
[16] Vinarskaja A1, Schulz W A, Ingenwerth M, et al. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis[Z]. Urol Oncol，2013 ，31(5):622
[17] Salem C, Liang G, Yc T, et al. Progressive increases in de Novo methylation of CpG islands in bladder cancer[J]. Cancer Res, 2000, 60(9):2473
[18] Basu M, Roy S S. Wnt/β-catenin pathway is regulated by PITX2 homeodomain protein and thus contributes to the proliferation of human ovarian adenocarcinoma cell, SKOV-3[J]. J Biol Chem, 2013, 288(6):4355
[19] Wei Q. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells[J]. J Biol Chem, 2005, 280(45):37790
[20] Hirose H, Ishii H, Mimori K, et al. The significance of PITX2 overexpression in human colorectal cancer[J]. Ann Surg Oncol, 2011, 18(10):3005

相似文献/References:

[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
　CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer（≤pT2N0M0）[J].Journal of Tianjin Medical University,2017,23(01):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
　MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(01):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
　LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(01):51.
[5]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
　FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(01):373.
[6]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
　WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(01):445.
[7]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[8]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
　LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(01):621.
[9]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.
[10]朱 亮,陈业刚.基于失巢凋亡相关标志物预测膀胱癌患者预后[J].天津医科大学学报,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
　ZHU Liang,CHEN Yegang.Prognosis of patients with bladder cancer predicted by biomarker associated with anoikis[J].Journal of Tianjin Medical University,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]

备注/Memo

备注/Memo:

基金项目 天津市卫生行业重点项目（16KG119）；天津市自然科学基金资助项目（18JCYBJC26200）
作者简介 王银蕾 （1991-），女，硕士在读，研究方向：外科学，泌尿外科；通信作者：胡海龙，E-mail：huhailong@tmu.edu.cn。

常用功能

更新日期/Last Update: 2020-04-16